Literature DB >> 16682596

Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study.

Sudha Cugati1, Jie Jin Wang, Elena Rochtchina, Paul Mitchell.   

Abstract

OBJECTIVE: To assess the 10-year incidence of retinal vein occlusion (RVO) and its predictors in an older population.
METHODS: The Blue Mountains Eye Study examined 3654 residents aged 49 years and older (82.4% response) from 1992 to 1994, reexamined 2335 residents (75.1% of survivors) from 1997 to 1999, and reexamined 1952 residents (75.6% of survivors) from 2002 to 2004. Incident RVO was assessed from stereoscopic retinal photographs. Kaplan-Meier cumulative 10-year incidence was calculated.
RESULTS: After excluding 47 residents with RVO at baseline and 171 residents with no photographs at either follow-up examination, 2346 residents were considered at risk of developing RVO. The cumulative 10-year incidence of RVO was 1.6%. Age was significantly associated with the incidence of RVO (P = .03, Mantel-Haenszel chi(2) test for trend). Factors predicting the incidence of RVO included mean arterial blood pressure (age-adjusted odds ratio [OR], 1.41 per 10-mm Hg increase), ocular perfusion pressure (OR, 1.71 per 10-mm Hg increase), obesity (OR, 2.16), and presence of retinal arteriolar wall signs (focal narrowing: OR, 3.37; arteriovenous nicking: OR, 4.09; and opacification: OR, 4.89).
CONCLUSIONS: Older age (> or =70 years), increasing mean arterial blood pressure, and atherosclerotic retinal vessel signs were significant predictors of incident RVO.

Entities:  

Mesh:

Year:  2006        PMID: 16682596     DOI: 10.1001/archopht.124.5.726

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  91 in total

1.  Branch retinal vein occlusion: the importance of the topographical distribution of retinal vessels among risk factors.

Authors:  Z Oztas; C Akkin; S Nalcaci; O Ilim; F Afrashi
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

2.  Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.

Authors:  Julie Blanc; Clémence Deschasse; Laurent Kodjikian; Corinne Dot; Alain-Marie Bron; Catherine Creuzot-Garcher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-31       Impact factor: 3.117

3.  Clinical Characteristics of Patients With CRVO in One Eye With Subsequent RVO in The Fellow Eye: A Retrospective Observational Study.

Authors:  Melissa Mei Hsia Chan; Akshay S Thomas; Stephen P Yoon; Diana Leitner; Sharon Fekrat
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-07-01       Impact factor: 1.300

4.  Association between visual status and mental health status in Thai rural elderly: a community-based study.

Authors:  Pear Pongsachareonnont; Nopphawan Uramphorn; Nuchanad Hounnaklang
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

5.  Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria.

Authors:  Marc Sorigue; Jordi Juncà; Elisa Orna; Nevena Romanic; Edurne Sarrate; Jordi Castellvi; Montse Soler; Ines Rodríguez-Hernandez; Evarist Feliu; Susana Ruiz
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

6.  Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion.

Authors:  Adnan Cinal; Focke Ziemssen; Karl U Bartz-Schmidt; Faik Gelisken
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-11-04       Impact factor: 3.117

7.  Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Authors:  Irini Chatziralli; George Theodossiadis; Marilita M Moschos; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-18       Impact factor: 3.117

8.  Extended field imaging using swept-source optical coherence tomography angiography in retinal vein occlusion.

Authors:  Shinji Kakihara; Takao Hirano; Yasuhiro Iesato; Akira Imai; Yuichi Toriyama; Toshinori Murata
Journal:  Jpn J Ophthalmol       Date:  2018-03-28       Impact factor: 2.447

9.  Retinal vein occlusion: pathophysiology and treatment options.

Authors:  Niral Karia
Journal:  Clin Ophthalmol       Date:  2010-07-30

10.  Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis).

Authors:  Gary Edd Fish
Journal:  Trans Am Ophthalmol Soc       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.